David M. Stack - Aug 5, 2021 Form 4 Insider Report for CHIASMA, INC (CHMA)

Role
Director
Signature
/s/ Lee G. Giguere, Attorney-in-Fact
Stock symbol
CHMA
Transactions as of
Aug 5, 2021
Transactions value $
$0
Form type
4
Date filed
8/5/2021, 05:51 PM
Previous filing
Jun 16, 2021
Next filing
Nov 18, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHMA Common Stock Disposed to Issuer -25K -100% 0 Aug 5, 2021 See Footnote F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHMA Stock Option (Right to Buy) Disposed to Issuer $0 -92K -100% $0.00* 0 Aug 5, 2021 Common Stock 92K $3.29 Direct F1, F4
transaction CHMA Stock Option (Right to Buy) Disposed to Issuer $0 -72.7K -100% $0.00* 0 Aug 5, 2021 Common Stock 72.7K $5.57 Direct F1, F4
transaction CHMA Stock Option (Right to Buy) Disposed to Issuer $0 -10K -100% $0.00* 0 Aug 5, 2021 Common Stock 10K $3.14 Direct F1, F4
transaction CHMA Stock Option (Right to Buy) Disposed to Issuer $0 -13K -100% $0.00* 0 Aug 5, 2021 Common Stock 13K $1.35 Direct F1, F4
transaction CHMA Stock Option (Right to Buy) Disposed to Issuer $0 -13K -100% $0.00* 0 Aug 5, 2021 Common Stock 13K $1.45 Direct F1, F4
transaction CHMA Stock Option (Right to Buy) Disposed to Issuer $0 -13K -100% $0.00* 0 Aug 5, 2021 Common Stock 13K $7.98 Direct F1, F4
transaction CHMA Stock Option (Right to Buy) Disposed to Issuer $0 -13K -100% $0.00* 0 Aug 5, 2021 Common Stock 13K $5.81 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

David M. Stack is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time").
F2 At the Effective Time, each share of common stock of the Company (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.396 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing five ordinary shares of Parent.
F3 Shares held by Three Colleens Investment LLC, a limited liability company jointly owned and managed by the Reporting Person and his spouse. This Form 4 shall not be deemed an admission of beneficial ownership of these shares by the Reporting Person except to the extent of his pecuniary interest therein.
F4 At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised prior to the Effective Time, whether or not vested, by virtue of the Merger, ceased to represent a right to acquire Shares and was converted into the option to purchase Parent ADSs (each an "Assumed Stock Option"). The number of Parent ADSs shall be equal to (i) number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.